- Home
- ATER vs NRXS Comparison
ATER vs NRXS Comparison
Compare ATER & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- NRXS
- Stock Information
- Founded
- ATER 2014
- NRXS 2011
- Country
- ATER United States
- NRXS United States
- Employees
- ATER N/A
- NRXS N/A
- Industry
- ATER Home Furnishings
- NRXS
- Sector
- ATER Consumer Discretionary
- NRXS
- Exchange
- ATER Nasdaq
- NRXS Nasdaq
- Market Cap
- ATER 15.5M
- NRXS 13.0M
- IPO Year
- ATER N/A
- NRXS 2023
- Fundamental
- Price
- ATER $2.11
- NRXS $2.27
- Analyst Decision
- ATER
- NRXS
- Analyst Count
- ATER 0
- NRXS 0
- Target Price
- ATER N/A
- NRXS N/A
- AVG Volume (30 Days)
- ATER 64.3K
- NRXS 29.8K
- Earning Date
- ATER 05-14-2025
- NRXS 05-12-2025
- Dividend Yield
- ATER N/A
- NRXS N/A
- EPS Growth
- ATER N/A
- NRXS N/A
- EPS
- ATER N/A
- NRXS N/A
- Revenue
- ATER $99,045,000.00
- NRXS $2,934,945.00
- Revenue This Year
- ATER N/A
- NRXS $138,883.78
- Revenue Next Year
- ATER $10.62
- NRXS $118.59
- P/E Ratio
- ATER N/A
- NRXS N/A
- Revenue Growth
- ATER N/A
- NRXS 27.52
- 52 Week Low
- ATER $1.56
- NRXS $1.33
- 52 Week High
- ATER $3.84
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- ATER 57.63
- NRXS 54.13
- Support Level
- ATER $1.86
- NRXS $1.94
- Resistance Level
- ATER $2.19
- NRXS $2.42
- Average True Range (ATR)
- ATER 0.12
- NRXS 0.26
- MACD
- ATER 0.04
- NRXS 0.01
- Stochastic Oscillator
- ATER 76.47
- NRXS 60.45
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).